AVCT Share Price LSE: Live Quote, Chart & Analyst Forecast

If you’re tracking Avacta Group (AVCT:LSE) ahead of a decision, the spread between analyst price targets and recent trading highs tells a story worth examining closely. Across six financial platforms, the stock carries a consensus “Buy” rating with 12-month targets ranging from 43p to 119p — yet the current price sits closer to the lower end of that range, creating a potential gap that investors need to understand before committing capital.

Current Price: 73.00p · Change Today: +1.00p (1.39%) · 52-Week Range: 26.00p – 86.40p · Recent Close: 72.00p · 52-Week High Date: Dec 17, 2025

Key facts at a glance

Is Avacta a buy hold or sell?

The short answer from analyst consensus leans bullish: most platforms flag AVCT as a “Buy.” Investing.com aggregates a Strong Buy rating based on 2 Buy recommendations with zero Holds or Sells over the past three months. MarketBeat records a solitary analyst assigning a Buy rating, while Marketscreener shows 3 analysts with a BUY consensus. The pattern across these platforms is consistent despite the varying number of contributors.

Analyst ratings summary

• Investing.com: Strong Buy — 2 Buy, 0 Hold, 0 Sell (Investing.com)
• MarketBeat: Buy — 1 analyst rating (MarketBeat)
• Marketscreener: BUY — 3 analysts consensus (Marketscreener)
• Investors Chronicle: 2 Buy, 1 Hold (as of 12-Mar-26) (Investors Chronicle)
• AskTraders: 1 Buy, 1 Hold — mixed view (AskTraders)

The variation in analyst count — ranging from 1 on MarketBeat to 4 on Investors Chronicle — means the consensus picture isn’t drawn from a uniform pool. Investors relying on aggregate ratings should note that a single additional analyst’s view can shift the consensus meaningfully in a thinly covered stock like AVCT.

Recent performance indicators

AVCT has experienced significant volatility over the past two years. The stock dropped more than 40% from the beginning of 2024, according to AskTraders, before rebounding more than 70% from mid-June lows. This recovery places the current price near the upper half of the 52-week range, but still below the 86.40p high recorded in December 2025.

“Analysts rate AVCT higher than average ‘medical’ companies, with a Buy consensus where peers typically see Hold ratings.” — MarketBeat

What are analysts’ price targets for AVCT?

Price targets for AVCT span a wide range, reflecting genuine uncertainty about the biotech’s pipeline outcomes and market timing. The average 12-month target from Investing.com’s 3 analysts sits at 93.33p, with a high of 119.00p and a low of 43.00p from Investors Chronicle — implying potential upside from the lower end of recent price data depending on which analyst you follow. MarketBeat records a 99p target (0.99 GBP) from its single analyst. Alpha Spread, which covers a broader target range, shows 84.92p average with extremes at 43.43p and 124.95p.

Short-term targets

Barclays offers the most immediate frame of reference: its Sell target of 71.00p sits just below the current 73.00p price, while its Buy target at 73.00p aligns almost exactly with today’s level. This effectively frames the current price as fairly valued within the broker’s internal model. Investors Chronicle data shows a median target of 72.00p from 3 analysts as of mid-March 2026 — essentially unchanged from current levels — with a high of 99.00p.

Long-term forecasts to 2026

• Investing.com average: 93.33p (3 analysts) (Investing.com)
• Investors Chronicle (4 analysts): 85.50p median, high 119.00p, low 43.00p (Investors Chronicle)
• Marketscreener: 0.8125 GBP average (approximately 81.25p) (Marketscreener)
• Alpha Spread: 84.92p average, high 124.95p, low 43.43p (Alpha Spread)
• TradingView: 71.33p average, max 99p, min 43p (TradingView)

The pattern across these platforms suggests that while the consensus sits around 85-93p, individual analyst convictions diverge sharply. Investors tracking AVCT should monitor whether forthcoming clinical data or partnership announcements push the lower-bound estimates upward — or whether the current price already discounts the optimistic scenario.

What is the potential upside for Avacta?

Calculating upside requires a reference price. Based on recent closes around 64-69p cited across multiple platforms, MarketBeat projects 53.86% upside to its 99p target. Investors Chronicle shows 23.02% upside from 69.50p to its 85.50p median target. The most aggressive case comes from Investing.com’s 93.33p average against a 28.32p reference — yielding substantial upside, though that reference price appears outdated relative to today’s 73.00p level.

Upside based on current price

• To Marketscreener average (0.8125 GBP): approximately 11% upside from 73.00p
• To Investors Chronicle median (85.50p): approximately 17% upside from 73.00p
• To Investing.com average (93.33p): approximately 28% upside from 73.00p
• To Investors Chronicle high (119.00p): approximately 63% upside from 73.00p

Comparison to 52-week high

The 52-week high of 86.40p sits below several target estimates, suggesting the stock has room to test fresh highs if catalyst events materialize. Investors Chronicle data indicates potential downside from median targets can reach -38.1%, which means the spread between best and worst case scenarios remains substantial.

“Long-term bulls and holders over the past 5 years will have seen impressive gains of more than 160%.” — AskTraders

The catch: historical gains of 160% over five years came during a period of different market conditions. Forward projections carry no guarantee of replication, and the biotech sector’s binary outcome profile means pipeline results can swing the price dramatically in either direction within short timeframes.

Does AVCT pay a dividend?

Based on available data, AVCT does not appear to pay a dividend. No verified fact in the research record indicates dividend payments, and the company’s status as a development-stage biotech makes regular shareholder distributions unlikely. Avacta Group has historically reinvested any operating cash flow into its pipeline rather than distributing profits.

Dividend history

The absence of dividend history aligns with typical early-stage biotech profiles, where capital is directed toward clinical programs rather than shareholder returns. Investors seeking income from AVCT should not expect dividend payments in the near term unless the company’s pipeline reaches commercialization milestones that generate sustained revenue.

Yield details

Given the lack of dividend payments, yield metrics are not applicable for AVCT at this time. Investors focused on total return rather than income should treat potential capital appreciation as the primary value driver for this position.

What are Avacta’s future growth prospects?

Avacta’s growth narrative hinges on its biotech pipeline, where revenue trajectory modeling from Alpha Spread shows a projected +15% CAGR over the next four years after a -52% contraction in the prior four-year period. This recovery projection depends on successful development milestones and potential licensing deals or commercial partnerships.

Key growth drivers

• Pipeline advancement: Clinical data readouts that could validate the company’s therapeutic approach
• Partnership potential: Licensing agreements with larger pharmaceutical companies that bring capital and validation
• Market positioning: AVCT rated above average medical sector peers by analyst consensus (Buy vs Hold) (MarketBeat)

Pipeline and prospects

The consensus upside potential ranges from 23% to 229% across sources, reflecting genuine disagreement about how quickly the market will price in pipeline value. Investors Chronicle notes downside risk from targets can reach -38.1%, illustrating that even the bear case leaves substantial value in the share price — suggesting the market is not dismissing the pipeline entirely.

Upsides

• Strong Buy consensus from multiple analyst platforms suggests institutional confidence in the pipeline
• Price targets extending to 119-125p represent 50-70% upside from current levels
• Rebound from 2024 lows (+70%) demonstrates capacity for rapid recovery when catalysts emerge
• Analyst coverage above peer average (Buy vs Hold) indicates relative value within the medical sector

Downsides

• Revenue contraction of -52% over four years signals operational challenges during development phase
• Price target spread of 60-70p between low and high estimates reflects genuine uncertainty
• Single-digit analyst coverage (1-4 analysts) limits consensus reliability and market awareness
• Barclays Sell target at 71.00p sits below current price, flagging potential overvaluation in near term
• No dividend yield means total return depends entirely on capital appreciation

“The consensus among analysts is that investors should ‘buy’ AVCT shares.” — MarketBeat (platform consensus)

“Mean consensus BUY — Number of Analysts: 3” — Marketscreener

Summary

Avacta Group presents a mixed picture for investors: the analyst consensus is decidedly bullish with targets extending 17-60% above the current 73.00p price, yet the thin analyst coverage and wide target spread introduce meaningful uncertainty. The stock has demonstrated volatility resilience with a 70% rebound from 2024 lows, and its rating exceeds medical sector peers — but revenue contraction history and lack of dividend income mean this is a pipeline bet, not a defensive holding. For growth-focused investors with above-average risk tolerance, the Buy consensus and potential 119p targets offer a compelling case; for income-oriented shareholders, AVCT does not fit the profile. The practical question is whether upcoming clinical milestones can narrow the gap between 71p near-term valuations and 93p-plus long-term targets before market patience runs thin.

Related reading: Deutsche Bank share price

Frequently asked questions

Sources: Investing.com · MarketBeat · Marketscreener · Investors Chronicle · Barclays Research Centre · Alpha Spread · TradingView · AskTraders